Avidity Biosciences begins a biomarker group in the FORTITUDE™ trial to seek potential fast-track approval for Delpacibart Braxlosiran (del-brax/AOC 1020).

Akeso has initiated patient recruitment for a Phase 3 study assessing Ivonescimab alongside Ligufalimab (CD47) as a first-line therapy for HNSCC.

HLX14, a biosimilar candidate for PROLIA/XGEVA (denosumab), has been accepted by the US Food and Drug Administration (FDA).

BridgeBio Oncology Therapeutics (BBOT) reports that the first patient has been treated with BBO-10203, a novel RAS:PI3Kα inhibitor.

Three Phase 3 studies have begun using Datopotamab Deruxtecan combinations in patients with advanced nonsquamous non-small cell lung cancer.

Alterome Therapeutics has dosed the first patient in its Phase 1 trial of ALTA2618 for AKT1 E17K-mutant solid tumors (AKTive-001).

Eisai showcases new clinical results indicating that the anti-MTBR tau antibody E2814 may block tau propagation at the 17th CTAD conference on Alzheimer's clinical trials.

Bitterroot Bio has confirmed the conclusion of participant enrollment for its Phase 1 trial assessing BRB-002 in healthy subjects.

GSK has struck a deal to buy CMG1A46 from Chimagen Biosciences to enhance its immunology portfolio.

LRallybio has received approval for clinical trial applications to conduct a Phase 2 study of RLYB212 in expectant mothers who are at increased risk of alloimmunization and FNAIT.

Immunome reveals strong preclinical results showcasing significant anti-tumor effects of IM-1021.

Aro Biotherapeutics has begun recruiting participants for a Phase 1b study of ABX1100 in individuals with Late-Onset Pompe Disease (LOPD).